Having worked with you gentlemen @AltonBoynton MarnixBosch over 20+ years ago, I’m still inspired to see the continued determination and passion you have for GBM patients! #DCVax #NWBO #ASCO2022

Allen Turner You have not gone unnoticed! Your contributions as an inventor of the #DCVax-Direct TTL device are important, so thank you! Northwest Bio $NWBO youtu.be/KiXbc2g6JyM&t=…

jamanetwork.com/journals/jamao… The DCVAX peer reviewed journal article is now available online! #DCVAX #SNO2022 #GBM

This is just the beginning. $NWBO #NWBO

Interview with Linda M. Liau, MD, PhD, author of Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma, in a podcast with H. Jack West, MD, FASCO. ja.ma/3EfhLEQ

PTRS #dcvax (Probability of Technical and Regulatory Success) >90% Upward adjustments: First in class therapy, unmet medical need, met primary and secondary endpoints (OS), compliance with health authority advice (ECA) Downward adjustments: Negligible  $NWBO

Use of ECAs in clinical trials with high morbidity conditions is nothing new. sciencedirect.com/science/articl… “FDA multidisciplinary reviews [and approval] for oncology submissions from 2014 to 2021 were screened to identify 7 cases with ECAs to support efficacy claims.” #dcvax $nwbo

Why $dcvax (#ForAllCancers) > targeted therapies Resistance mechanisms limits the success of precision medicine (e.g targeted therapies) in cancer A new batch of DCVax-L (i.e second course) can be made upon recurrence. Tx targets not lost, as they are with targeted therapies

$nwbo DCVax Value Platform (abr.) -Need for New Tx Options in GBM: Lack of approved Tx. Poor PX given lack of effective therapies -Value of #DCVax in GBM: Clinically meaningful OS. Favorable safety. Cost effective “Price is what you pay; Value is what [patients] get” -Buffett

“Tumor lysate-loaded DCs (DCVax-L) have acquired additional T cell stimulatory capacity, resulting in more late generation T cells to fight the tumor” -Marnix Bosch #asco2023 #dcvax $nwbo

NICE was the first HTA body in EU5 to issue a favourable reimbursement for a CAR-T cell therapy, in less than 10 days after obtaining MA. Benefits of #DCVax-L > CAR-Ts: Reduced AE, LT immune responses, Potential of combos, Targeting multiple AGs, Ease of manufacturing and admin

How $NWBO is revolutionizing the healthcare industry? ✔️Breadth and depth of Tx strategies ✔️Unlocking the community and removing the need for an ATC ✔️Addressing the challenge of tumor heterogeneity in solid tumors with proteomic and T cell studies#dcvax stocks.apple.com/ARoP7Wxp-S5mSm…

Limited treatment options for GBM patients is disheartening. Thankfully, #DCVax significantly transforms the Overall Survival of SOC. ATL-DC (mono) and + poly-ICLC will change the guidelines for evidence-based recommendations.

What’s the cost advantage of #DCVax administered in the community setting? “For cilta-cel CAR-T therapy administered exclusively in an inpatient setting, costs amounted to $160,933 over 12 months.” #nwbo #Walgreens ncbi.nlm.nih.gov/pmc/articles/P…

☑️Long-term survivors have now been followed for over 10 years ☑️OS (placebo: 7.7 months, poly-ICLC: 52.5 months, and resiquimod: 16.7 months) ☑️PFS (placebo: 5.5 months, poly-ICLC: 31.4 months and resiquimod: 8.1 months) #DCVax #Mercidencel $NWBO nature.com/articles/s4146…

Maximizing #DCVax-L Revenue at Launch = (⬆️% capacity slots used) x (⬆️% patient infusions) x (cost per infusion). 🚀Optimize MHRA label negotiations 🚀Educate on patient selection & tumor banking 🚀Maximize slot allocation for the right patients. $NWBO astctjournal.org/article/S2666-…

Key ingredients for an award-winning label for #DCVax 📖 ✨ One: A broad indication as an autologous dendritic cell therapy indicated for the treatment of adult patients with newly diagnosed or recurrent glioblastoma. ✨ Two: Minimal safety warnings. fda.gov/media/115378/d…

What should all brain cancer patients do while $NWBO waits for #DCVax approval? ‼️ Bank Your Tumor ‼️ The UCLA Brain Tumor Tissue Repository (BTTR) houses over 11,000 brain tumor samples, making it the largest of its kind for tissue-based research. uclahealth.org/cancer/cancer-…

“Immune Checkpoint Inhibitors Market size was valued at USD 47.4 billion from 2024 to 2032. This market is witnessing strong growth, primarily driven by… a rising demand for advanced, personalized cancer therapies.” #DCVax $NWBO gminsights.com/industry-analy…